Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on May 7, 2025
Oculis to Present at Upcoming May Investor Conferences
GlobeNewswire
·
May 7, 2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, …
Prime Biome Reviews Fixed What Doctors Couldn’t – In Just Weeks! A Reality Based, Self Trial, Facts and Figure Which Revealed the Truth!
GlobeNewswire
·
May 7, 2025
St. Petersburg, Florida, May 07, 2025 (GLOBE NEWSWIRE) -- as per studies a person's complete health depends on gut and skin health, especially in our fast-paced environment. People are most concerned about their stomach and skin issues, which can lead to …
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
GlobeNewswire
·
May 7, 2025
Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006) Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence In vivo demonstration of ammonia …
PrimeBiome Reviews Consumer Reports: Critical Complaints & Customer Reviews Exposed!
GlobeNewswire
·
May 7, 2025
ANCHORAGE, Alaska, May 07, 2025 (GLOBE NEWSWIRE) -- PrimeBiome is a natural skin and gut health formula that has been gaining immense popularity in the market. As per the claims of the manufacturers, this formula is created using scientifically proven …
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
GlobeNewswire
·
May 7, 2025
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform therapeutic strategies beyond ARDS, …
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
GlobeNewswire
·
May 7, 2025
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and safety for six months or more following …